NovoCure Ltd Insider Trading for September 2019
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NovoCure Ltd.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NovoCure Ltd for September 2019.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Option Exercise | M | 7.03 | 1,961 | 13,786 | 58,286 | |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Option Exercise | M | 7.03 | 1,961 | 13,786 | 58,286 | |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Option Exercise | M | 3.44 | 4,031 | 13,867 | 90,632 | |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Option Exercise | M | 3.44 | 4,031 | 13,867 | 90,632 | |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Option Exercise | M | 3.44 | 2,000 | 6,880 | 27,069 | |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Option Exercise | M | 3.44 | 2,000 | 6,880 | 27,069 | |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 81.19 | 300 | 24,358 | 87,179 | 87.5 K to 87.2 K (-0.34 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 81.19 | 300 | 24,358 | 87,179 | 87.5 K to 87.2 K (-0.34 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 80.56 | 1,661 | 133,804 | 87,479 | 89.1 K to 87.5 K (-1.86 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 80.56 | 1,661 | 133,804 | 87,479 | 89.1 K to 87.5 K (-1.86 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Buy | M | 7.03 | 1,961 | 13,786 | 89,140 | 87.2 K to 89.1 K (+2.25 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Buy | M | 7.03 | 1,961 | 13,786 | 89,140 | 87.2 K to 89.1 K (+2.25 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 81.18 | 700 | 56,824 | 87,179 | 87.9 K to 87.2 K (-0.80 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 81.18 | 700 | 56,824 | 87,179 | 87.9 K to 87.2 K (-0.80 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 80.50 | 3,331 | 268,155 | 87,879 | 91.2 K to 87.9 K (-3.65 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 80.50 | 3,331 | 268,155 | 87,879 | 91.2 K to 87.9 K (-3.65 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Buy | M | 3.44 | 4,031 | 13,867 | 91,210 | 87.2 K to 91.2 K (+4.62 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Buy | M | 3.44 | 4,031 | 13,867 | 91,210 | 87.2 K to 91.2 K (+4.62 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 81.19 | 300 | 24,358 | 87,179 | 87.5 K to 87.2 K (-0.34 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 81.19 | 300 | 24,358 | 87,179 | 87.5 K to 87.2 K (-0.34 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 80.53 | 1,700 | 136,899 | 87,479 | 89.2 K to 87.5 K (-1.91 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 80.53 | 1,700 | 136,899 | 87,479 | 89.2 K to 87.5 K (-1.91 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Buy | M | 3.44 | 2,000 | 6,880 | 89,179 | 87.2 K to 89.2 K (+2.29 %) |
| Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Buy | M | 3.44 | 2,000 | 6,880 | 89,179 | 87.2 K to 89.2 K (+2.29 %) |
| Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 25,000 | 86,000 | 94,663 | |
| Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 25,000 | 86,000 | 119,663 | |
| Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 79.01 | 22,300 | 1,761,856 | 87,179 | 109.5 K to 87.2 K (-20.37 %) |
| Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 78.33 | 2,700 | 211,478 | 109,479 | 112.2 K to 109.5 K (-2.41 %) |
| Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 25,000 | 86,000 | 112,179 | 87.2 K to 112.2 K (+28.68 %) |
| Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 80.96 | 400 | 32,384 | 87,179 | 87.6 K to 87.2 K (-0.46 %) |
| Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 80.27 | 13,502 | 1,083,792 | 87,579 | 101.1 K to 87.6 K (-13.36 %) |
| Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 79.24 | 11,098 | 879,372 | 101,081 | 112.2 K to 101.1 K (-9.89 %) |
| Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 25,000 | 86,000 | 112,179 | 87.2 K to 112.2 K (+28.68 %) |
| Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 25,000 | 86,000 | 144,663 | |
| Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 25,000 | 86,000 | 169,663 | |
| Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 81.05 | 201 | 16,291 | 87,179 | 87.4 K to 87.2 K (-0.23 %) |
| Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 80.51 | 10,107 | 813,694 | 87,380 | 97.5 K to 87.4 K (-10.37 %) |
| Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 79.42 | 6,499 | 516,151 | 97,487 | 104 K to 97.5 K (-6.25 %) |
| Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 78.50 | 8,193 | 643,142 | 103,986 | 112.2 K to 104 K (-7.30 %) |
| Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 25,000 | 86,000 | 112,179 | 87.2 K to 112.2 K (+28.68 %) |
| Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 79.19 | 4,061 | 321,599 | 87,179 | 91.2 K to 87.2 K (-4.45 %) |
| Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 78.72 | 11,015 | 867,057 | 91,240 | 102.3 K to 91.2 K (-10.77 %) |
| Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 77.52 | 4,008 | 310,692 | 102,255 | 106.3 K to 102.3 K (-3.77 %) |
| Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 76.37 | 3,974 | 303,478 | 106,263 | 110.2 K to 106.3 K (-3.60 %) |
| Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 75.56 | 1,942 | 146,738 | 110,237 | 112.2 K to 110.2 K (-1.73 %) |
| Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 25,000 | 86,000 | 112,179 | 87.2 K to 112.2 K (+28.68 %) |
| Sep 12 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 3.44 | 5,000 | 17,200 | 14,743 | |
| Sep 12 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 76.63 | 5,000 | 383,150 | 69,504 | 74.5 K to 69.5 K (-6.71 %) |
| Sep 12 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 3.44 | 5,000 | 17,200 | 74,504 | 69.5 K to 74.5 K (+7.19 %) |
| Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 25,000 | 86,000 | 194,663 | |
| Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 25,000 | 86,000 | 219,663 | |
| Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 76.45 | 5,709 | 436,447 | 87,179 | 92.9 K to 87.2 K (-6.15 %) |
| Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 75.28 | 19,291 | 1,452,188 | 92,888 | 112.2 K to 92.9 K (-17.20 %) |
| Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 25,000 | 86,000 | 112,179 | 87.2 K to 112.2 K (+28.68 %) |
| Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 84.41 | 200 | 16,882 | 87,179 | 87.4 K to 87.2 K (-0.23 %) |
| Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 82.74 | 1,100 | 91,011 | 87,379 | 88.5 K to 87.4 K (-1.24 %) |
| Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 82.05 | 10,800 | 886,129 | 88,479 | 99.3 K to 88.5 K (-10.88 %) |
| Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 80.92 | 4,400 | 356,061 | 99,279 | 103.7 K to 99.3 K (-4.24 %) |
| Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 79.73 | 1,643 | 130,990 | 103,679 | 105.3 K to 103.7 K (-1.56 %) |
| Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 78.70 | 6,857 | 539,673 | 105,322 | 112.2 K to 105.3 K (-6.11 %) |
| Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 25,000 | 86,000 | 112,179 | 87.2 K to 112.2 K (+28.68 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 21.15 | 30,414 | 643,256 | 86,513 | |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 7.15 | 56,874 | 406,649 | 97,799 | |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 6.72 | 11,632 | 78,167 | 0 | |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 6.72 | 59,520 | 399,974 | 0 | |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 89.86 | 1,200 | 107,828 | 53,900 | 55.1 K to 53.9 K (-2.18 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.86 | 2,900 | 257,703 | 55,100 | 58 K to 55.1 K (-5.00 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.18 | 14,888 | 1,312,794 | 58,000 | 72.9 K to 58 K (-20.43 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 86.86 | 11,426 | 992,440 | 72,888 | 84.3 K to 72.9 K (-13.55 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 21.15 | 30,414 | 643,256 | 84,314 | 53.9 K to 84.3 K (+56.43 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 89.87 | 4,031 | 362,262 | 53,900 | 57.9 K to 53.9 K (-6.96 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.97 | 7,869 | 700,129 | 57,931 | 65.8 K to 57.9 K (-11.96 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.22 | 24,083 | 2,124,482 | 65,800 | 89.9 K to 65.8 K (-26.79 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 86.95 | 20,891 | 1,816,556 | 89,883 | 110.8 K to 89.9 K (-18.86 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 7.15 | 56,874 | 406,649 | 110,774 | 53.9 K to 110.8 K (+105.52 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 89.97 | 400 | 35,988 | 53,900 | 54.3 K to 53.9 K (-0.74 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.94 | 929 | 82,622 | 54,300 | 55.2 K to 54.3 K (-1.68 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.19 | 6,065 | 534,897 | 55,229 | 61.3 K to 55.2 K (-9.89 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 86.88 | 4,238 | 368,206 | 61,294 | 65.5 K to 61.3 K (-6.47 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 6.72 | 11,632 | 78,167 | 65,532 | 53.9 K to 65.5 K (+21.58 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 89.90 | 2,300 | 206,759 | 53,900 | 56.2 K to 53.9 K (-4.09 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.82 | 6,616 | 587,620 | 56,200 | 62.8 K to 56.2 K (-10.53 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.17 | 28,340 | 2,498,766 | 62,816 | 91.2 K to 62.8 K (-31.09 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 86.85 | 22,264 | 1,933,539 | 91,156 | 113.4 K to 91.2 K (-19.63 %) |
| Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 6.72 | 59,520 | 399,974 | 113,420 | 53.9 K to 113.4 K (+110.43 %) |
| Sep 03 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 92.00 | 500 | 46,000 | 134,601 | 135.1 K to 134.6 K (-0.37 %) |
| Sep 03 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 91.60 | 65,768 | 6,024,612 | 135,101 | 200.9 K to 135.1 K (-32.74 %) |
| Sep 03 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 90.58 | 57,913 | 5,245,586 | 200,869 | 258.8 K to 200.9 K (-22.38 %) |
| Sep 03 2019 | NVCR | NovoCure Ltd | PHILLIPS CHARLES G III | Director | Option Exercise | M | 6.72 | 22,000 | 147,840 | 40,607 | |
| Sep 03 2019 | NVCR | NovoCure Ltd | PHILLIPS CHARLES G III | Director | Sell | S | 92.10 | 400 | 36,839 | 9,504 | 9.9 K to 9.5 K (-4.04 %) |
| Sep 03 2019 | NVCR | NovoCure Ltd | PHILLIPS CHARLES G III | Director | Sell | S | 91.46 | 12,908 | 1,180,540 | 9,904 | 22.8 K to 9.9 K (-56.58 %) |
| Sep 03 2019 | NVCR | NovoCure Ltd | PHILLIPS CHARLES G III | Director | Sell | S | 90.63 | 8,692 | 787,739 | 22,812 | 31.5 K to 22.8 K (-27.59 %) |
| Sep 03 2019 | NVCR | NovoCure Ltd | PHILLIPS CHARLES G III | Director | Buy | M | 6.72 | 22,000 | 147,840 | 31,504 | 9.5 K to 31.5 K (+231.48 %) |
| Sep 03 2019 | NVCR | NovoCure Ltd | VERNON W ANTHONY | Director | Sell | S | 91.03 | 100,000 | 9,103,100 | 158,589 | 258.6 K to 158.6 K (-38.67 %) |